The peptide landscape in men's health shifted dramatically between 2023 and 2025. The FDA's ongoing review of bulk drug substances used in compounding — particularly the Category 2 designations — pulled several popular peptides from legitimate compounding pharmacy menus. If your optimization protocol included specific peptides two years ago, the availability picture has changed.
What Happened: The Category System
The FDA maintains a list of bulk drug substances that can be used by compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA evaluates nominated substances and places them into categories:
- Category 1: Eligible for compounding. The substance meets the FDA's evaluation criteria for safety, identity, and characterization.
- Category 2: Not eligible for compounding. The substance lacks adequate safety data, hasn't been adequately characterized, or presents other concerns.
- Category 3: Under review. The FDA hasn't made a final determination.
Several peptides commonly used in men's health clinics received Category 2 designations, meaning compounding pharmacies that comply with FDA guidance can no longer legally produce them.
What's Restricted
| Peptide | Former Use | FDA Status |
|---|---|---|
| BPC-157 (Body Protection Compound) | Tissue repair, gut healing, injury recovery | Category 2 — no adequate safety data in humans |
| Ipamorelin | Growth hormone secretion (GHS receptor agonist) | Category 2 — never FDA-approved for any indication |
| CJC-1295 (with and without DAC) | Sustained GHRH-like GH secretion | Category 2 — never FDA-approved |
| GHK-Cu (Copper peptide) | Skin healing, wound repair, anti-aging | Category 2 determination pending/restricted in some states |
| Thymosin Alpha-1 | Immune modulation | Category 2 — previously available from 503B pharmacies |
What's Still Available
| Peptide | Use | Legal Basis |
|---|---|---|
| Sermorelin | GH secretion (GHRH fragment) | Previously FDA-approved (Geref); strongest compounding basis |
| PT-141 (Bremelanotide) | Sexual desire (MC4R agonist) | FDA-approved as Vyleesi (for women); compounded off-label for men |
| Semaglutide* | Weight loss (GLP-1 RA) | FDA-approved; compounding during shortage per 503B rules |
| Tirzepatide* | Weight loss (GLP-1/GIP dual agonist) | FDA-approved; compounding during shortage per 503B rules |
| NAD+ | Cellular energy, anti-aging | Generally available for compounding; not Category 2 |
| Oxytocin | Sexual function, bonding (in compounded ED formulas) | FDA-approved for obstetric use; compounded off-label |
*GLP-1 compounding status depends on shortage determinations that change. Check current FDA shortage status.
What This Means for Men's Protocols
GH Axis: Sermorelin Is the Survivor
With ipamorelin and CJC-1295 restricted, sermorelin has become the primary compounded option for men seeking growth hormone axis support. Its prior FDA approval gives it the strongest legal basis for compounding. Tesamorelin (Egrifta) is an FDA-approved GHRH analog but is only commercially available for HIV-associated lipodystrophy — off-label prescribing is possible but insurance won't cover it for optimization purposes.
BPC-157: The Most-Missed Peptide
BPC-157 was probably the most widely used peptide in men's optimization for injury recovery and gut health. Its Category 2 designation was based on the absence of human safety data — not evidence of harm. The peptide has extensive animal data showing tissue-protective effects, but no Phase I human trial has ever been published. Clinics that continued compounding BPC-157 after the ruling face legal and regulatory risk.
The Underground Alternative
Category 2 restrictions apply to FDA-regulated compounding pharmacies. Research chemical suppliers and gray-market peptide sources still sell restricted peptides. The risks are obvious: no quality control, no potency verification, no sterility assurance, and no legal protection. Men who choose this route are accepting pharmaceutical risks that compounding pharmacies at least partially mitigate.
How to Evaluate Your Current Protocol
Peptide Audit Checklist
- Ask your clinic: Which compounding pharmacy fills your peptide prescriptions? Are they 503A or 503B registered?
- Check Category status: Is the specific peptide you're using currently Category 1 (eligible) or Category 2 (restricted)?
- Verify sourcing: If your clinic is still offering a Category 2 peptide, ask how — are they using a pharmacy that hasn't complied with FDA guidance, or has the substance been reclassified?
- Evaluate alternatives: For most peptide goals (GH support, recovery, immune modulation), alternatives exist within the legally available list.
The Bottom Line
The Menu Is Shorter, the Evidence Bar Is Rising
The FDA's Category 2 actions pruned the peptide landscape significantly. What remains — sermorelin, PT-141, NAD+, and a handful of others — has stronger regulatory footing and, in some cases, actual FDA-approval histories. Men should view this as a quality filter, not a loss: the peptides that survived generally have better evidence or regulatory pedigree than those that didn't.